Noruxol (Collagenase Clostridium Histolyticum, Protease)

Collagenase Clostridium Histolyticum, Protease, the active ingredient in Noruxol, is a collagenase enzyme presented as a topical formulation for topical use. It enzymatically debrides necrotic tissue in chronic cutaneous wounds and supports healing in dermatologic applications. Approved in the European Union, it is indicated for use under medical supervision in patients with non‑healing wounds where removal of dead tissue is required.

GNH USA supplies Noruxol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Noruxol is a collagenase enzyme used in dermatology to facilitate enzymatic debridement of chronic wounds. - Chronic cutaneous wounds: removes necrotic tissue to promote granulation and accelerate healing. - Venous leg ulcers: aids in clearing dead tissue, improving wound bed preparation for further therapy. - Pressure injuries (stage II–III): assists in debridement, supporting transition to healthy tissue formation.

Topical application of Noruxol may be associated with local and systemic adverse reactions.

Common Side Effects: - Erythema at the application site. - Pain or mild burning sensation. - Itching or pruritus. - Swelling or edema of surrounding skin. - Mild local infection. - Transient tenderness.

Serious or Rare Side Effects: - Severe allergic reaction, including anaphylaxis. - Extensive skin necrosis beyond the target area. - Systemic hypersensitivity reactions. - Cellulitis or deep tissue infection. - Worsening of the ulcer or delayed healing. - Rare systemic toxicity.

When prescribing Noruxol, clinicians should consider several precautionary measures to ensure safe use. - Assess wound type: confirm presence of necrotic tissue before use. - Avoid use on healthy skin: limit application to areas with documented necrosis. - Monitor for infection: watch for signs of secondary infection during treatment. - Do not combine with other proteolytic agents: avoid additive tissue damage. - Pregnancy and lactation: use only if benefit outweighs risk (category unknown). - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Noruxol may interact with other topical or systemic agents that affect proteolytic activity or wound healing.

Major Interactions (Avoid): - Concurrent use with other topical proteases or debriding agents: may cause excessive tissue breakdown. - Systemic protease inhibitors (e.g., aprotinin): may reduce enzymatic efficacy.

Moderate Interactions (Monitor Closely): - Topical antibiotics: may alter local microbiome, monitor for infection. - Corticosteroid creams: may impair healing, assess wound response. - Radiation therapy to the area: may increase skin sensitivity.